SNHG16 and COVID-19: Down-regulation of SNHG16 in COVID-19 patients might result in decreased proportion of γδ1 T cells, thus activation of pro-inflammatory cascades and pulmonary fibrosis, since some subsets of γδ T cells regulate immunosuppressive functions and induce immune tolerance in certain contexts [25].